Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VTGN
stocks logo

VTGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
145.80K
-20.33%
-0.366
-20.43%
218.60K
-6.58%
-0.372
-15.45%
--
--
-0.410
-12.77%
Estimates Revision
The market is revising Upward the revenue expectations for Vistagen Therapeutics, Inc. (VTGN) for FY2026, with the revenue forecasts being adjusted by 71.36% over the past three months. During the same period, the stock price has changed by 20.56%.
Revenue Estimates for FY2026
Revise Upward
up Image
+71.36%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+6.3%
In Past 3 Month
Stock Price
Go Up
up Image
+20.56%
In Past 3 Month
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 15.50 USD with a low forecast of 12.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 15.50 USD with a low forecast of 12.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.280
sliders
Low
12.00
Averages
15.50
High
19.00
Current: 4.280
sliders
Low
12.00
Averages
15.50
High
19.00
Lucid Capital
NULL
to
Buy
initiated
$19
2025-09-02
Reason
Lucid Capital
Price Target
$19
2025-09-02
initiated
NULL
to
Buy
Reason
Lucid Capital initiated coverage of Vistagen with a Buy rating and $19 price target. The company is developing the first drug, fasedienol, to treat social anxiety disorder episodically, when needed, the analyst tells investors in a research note. The firm views social anxiety disorder episodically as an underserved condition.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vistagen Therapeutics Inc (VTGN.O) is -2.75, compared to its 5-year average forward P/E of -3.64. For a more detailed relative valuation and DCF analysis to assess Vistagen Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.64
Current PE
-2.75
Overvalued PE
-0.44
Undervalued PE
-6.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
162.61
Current PS
0.00
Overvalued PS
422.93
Undervalued PS
-97.71
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

VTGN News & Events

Events Timeline

(ET)
2025-12-01
09:11:00
Vistagen Appoints Nick Tressler as CFO Effective Immediately
select
2025-11-26 (ET)
2025-11-26
08:38:50
Vistagen showcases preliminary PH80 findings at Menopause Society conference
select
2025-11-13 (ET)
2025-11-13
16:31:41
Vistagen Announces Q2 Earnings Per Share of 54 Cents, Exceeding Consensus Estimate of 44 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-01NASDAQ.COM
Vistagen Appoints Nick Tressler as Chief Financial Officer

  • New CFO Appointment: Vistagen Therapeutics has appointed Nick Tressler as Chief Financial Officer, who previously served as CFO of Dynex Technologies.

  • Experience in Life Sciences: Tressler brings over 20 years of experience in the life sciences industry to his new role at Vistagen.

  • Incentive Stock Options: The board of Vistagen has granted Tressler an incentive option to purchase up to 150,000 shares of the company's common stock.

  • Disclaimer: The views expressed in the article do not necessarily reflect those of Nasdaq, Inc.

[object Object]
Preview
9.0
11-26Newsfilter
Vistagen Presents PH80's Rapid Relief Potential for Menopausal Symptoms at 2025 Meeting
  • Rapid Mechanism of Action: Research presented by Vistagen at the 2025 Menopause Society Annual Meeting indicates that PH80 can rapidly reduce autonomic nervous system activity after intranasal administration without being absorbed into the bloodstream, showcasing its potential as a non-hormonal, non-systemic treatment option that could provide effective relief for millions of women.
  • Safety Profile: The findings demonstrate that PH80 does not bind to steroid hormone receptors or neurotransmitter receptors, thereby reducing the risk of abuse and enhancing its appeal as a novel therapeutic option, addressing a critical need in women's health.
  • Physiological Biomarker Impact: PH80 induces rapid effects on physiological markers of autonomic activity within seconds of intranasal administration, providing significant scientific backing for its clinical application and potentially transforming the treatment landscape for menopausal symptoms.
  • Historical Research Insights: The early research data obtained by Vistagen through its acquisition of Pherin reveals critical insights into PH80's mechanism of action, indicating its strategic value in future drug development and potentially advancing the company's position in the biopharmaceutical sector.
[object Object]
Preview
9.5
11-15NASDAQ.COM
Transcript of Vistagen's (VTGN) Earnings Call for Q2 2026
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vistagen Therapeutics Inc (VTGN) stock price today?

The current price of VTGN is 4.28 USD — it has increased 14.75 % in the last trading day.

arrow icon

What is Vistagen Therapeutics Inc (VTGN)'s business?

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.

arrow icon

What is the price predicton of VTGN Stock?

Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 15.50 USD with a low forecast of 12.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vistagen Therapeutics Inc (VTGN)'s revenue for the last quarter?

Vistagen Therapeutics Inc revenue for the last quarter amounts to 258.00K USD, increased 40.98 % YoY.

arrow icon

What is Vistagen Therapeutics Inc (VTGN)'s earnings per share (EPS) for the last quarter?

Vistagen Therapeutics Inc. EPS for the last quarter amounts to -0.54 USD, increased 28.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vistagen Therapeutics Inc (VTGN)'s fundamentals?

The market is revising Upward the revenue expectations for Vistagen Therapeutics, Inc. (VTGN) for FY2026, with the revenue forecasts being adjusted by 71.36% over the past three months. During the same period, the stock price has changed by 20.56%.
arrow icon

How many employees does Vistagen Therapeutics Inc (VTGN). have?

Vistagen Therapeutics Inc (VTGN) has 56 emplpoyees as of December 05 2025.

arrow icon

What is Vistagen Therapeutics Inc (VTGN) market cap?

Today VTGN has the market capitalization of 169.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free